Significant Reduction In Total Cholesterol Research Articles

SLCO1B1 and ABCB1 variants synergistically influencethe atorvastatin treatment response in South Indian coronary artery disease patients.

Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the drug efficacy in coronary artery diseasepatients. Aim: To study the effect of genetic variants involved in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods: Genotyping was performed using 5'-hydrolysis probe method (n=412), and the studyevaluated the treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density lipoprotein cholesterol(LDL-C) were observed in SLCO1B1-rs4149056, rs4363657and ABCB1-rs1045642 genotypes. The combined genotypes of ABCB1 and SLCO1B1showed a strong synergistic effect in reducing the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction. Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin, and this may be useful in genotype-guided statin therapy for coronary artery disease patients.

Novel APOB nonsense variant related to familial hypobetalipoproteinemia and hepatic steatosis: A case report and review

Hereditary familial hypobetalipoproteinemia (FHBL) is a syndrome caused by variants in the APOB gene, that cause a defect in the secretion and mobilization of liver lipids to peripheral tissues, associated with the synthesis of truncated ApoB100 apolipoproteins. This condition causes significant reduction in total cholesterol (TC), low-density lipoproteins (LDL), very low-density proteins (VLDL) and serum triglyceride levels, with unchanged high-density lipoprotein (HDL) cholesterol levels. Herein we present the case of a middle-aged woman diagnosed with FHBL and hepatic steatosis, heterozygous for c.4698C>A; (p.Tyr1566Ter) variant in APOB. The variant presented herein showed high expressiveness in the two generations of individuals analyzed and has not yet being described in the medical literature. Early diagnosis and screening for associated metabolic comorbidities such as metabolic fatty liver disease and its subsequent progression to fibrosis are the two main goals in the treatment of this condition, in order to prevent medium to long term potential complications.

The effects of guar gum supplementation on lipid profile in adults: a GRADE-assessed systematic review, meta-regression and dose-response meta-analysis of randomised placebo-controlled trials.

Recent meta-analytic work indicated that guar gum supplementation might improve lipid profile markers in different populations. However, critical methodological limitations such as the use of some unreliable data and the lack of inclusion of several relevant studies, and the scarcity in assessments of regression and dose-specific effects make it difficult to draw meaningful conclusions from the meta-analysis. Therefore, current evidence regarding the effects of guar gum supplementation on lipid profile remains unclear. The present systematic review, meta-regression and dose-response meta-analysis aimed to examine the effects of guar gum supplementation on lipid profile (total cholesterol (TC), LDL, TAG and HDL) in adults. Relevant studies were obtained by searching the PubMed, SCOPUS, Embase and Web of Science databases (from inception to September 2021). Weighted mean differences (WMD) and 95 % CI were estimated via a random-effects model. Heterogeneity, sensitivity analysis and publication bias were reported using standard methods. Pooled analysis of nineteen randomised controlled trials (RCT) revealed that guar gum supplementation led to significant reductions in TC (WMD: -19·34 mg/dl, 95 % CI -26·18, -12·49, P < 0·001) and LDL (WMD: -16·19 mg/dl, 95 % CI -25·54, -6·83, P = 0·001). However, there was no effect on TAG and HDL among adults in comparison with control group. Our outcomes suggest that guar gum supplementation lowers TC and LDL in adults. Future large RCT on various populations are needed to show further beneficial effects of guar gum supplementation on lipid profile and establish guidelines for clinical practice.

Therapeutic Potential of Artichoke in the Treatment of Fatty Liver: A Systematic Review and Meta-Analysis.

Nonalcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can lead to liver cirrhosis, liver cancer, and death. Artichoke leaf extract (ALE) is well known in folk medicine for its hepatoprotective effect. Till recent times, no sufficient data from randomized clinical trials (RCTs) exist to support such use. This meta-analysis summarizes evidence from recent RCTs that evaluated ALE in NAFLD patients. Electronic databases were searched for RCTs that used ALE in NAFLD patients. The random-effects model was used to pool effect sizes (standardized change score). Data synthesis from five RCTs (333 patients) showed that ALE resulted in a significant reduction in alanine aminotransferase (standardized mean difference [SMD]: 1.1; 95% confidence interval [CI], 0.79-1.73; P < .001) and aspartate aminotransferase levels (SMD: 1.01; 95% CI, 0.52-1.51; P < .001) compared with the control group. ALE also resulted in a significant reduction in total cholesterol (SMD: 0.98; 95% CI, 0.53-1.43; P = .004), low-density lipoprotein (SMD: 0.96; 95% CI, 0.3-1.62; P < .001) and triglycerides (SMD: 0.95; 95% CI, 0.58-1.32; P < .001). The current review provides evidence from RCTs to support the use of ALE as a hepatoprotective agent in NAFLD patients. The study was registered on the PROSPERO database with the Registration No. CRD42020182502 (https://www.crd.york.ac.uk/prospero).

Role of Phytoestrogen-Rich Bioactive Substances (Linum usitatissimum L., Glycine max L., Trifolium pratense L.) in Cardiovascular Disease Prevention in Postmenopausal Women: A Systematic Review and Meta-Analysis.

The aim of this report was to determine the impact of flaxseed, soy and red clover, and their bioactive substances on the lipid profile in postmenopausal women in cardiovascular diseases prevention. We used the following databases: MEDLINE (PubMed), EMBASE and the Cochrane Library. Meta-analysis indicates that the intake of flaxseed by postmenopausal women is associated with a statistically significant reduction in total cholesterol (TC) levels (weighted-mean difference (WMD) = −0.26; 95% confidence interval (95% CI): −0.38 to −0.13; p = 0.0001), low-density lipoprotein cholesterol (LDL-C) levels (WMD = −0.19; 95% CI: −0.30 to −0.08; p = 0.0006), and high-density lipoprotein cholesterol (HDL-C) levels (WMD = −0.06; 95% CI: −0.11 to −0.01; p = 0.0150). The effect of soy protein on the lipid profile showed a significant decrease in TC levels: WMD = −0.15; 95% CI: −0.25–0.05; p = 0.0048, LDL-C levels: WMD = −0.15; 95% CI: −0.25–0.05; p = 0.0067, as well as a significant increase in HDL-C levels: WMD = 0.05; 95% CI: 0.02–0.08; p = 0.0034. Changes in the lipid profile showed a significant reduction in TC levels after the use of red clover (WMD = −0.11; 95% CI: −0.18–−0.04; p = 0.0017) and a significant increase in HDL-C levels (WMD = 0.04; 95% CI: 0.01 to 0.07; p = 0.0165). This meta-analysis provides evidence that consuming flaxseed, soy and red clover can have a beneficial effect on lipids in postmenopausal women and suggest a favorable effect in preventing cardiovascular diseases.

Effects of Methanolic Extract of Mistiltoe (Viscum Album) on Alloxan Induced Diabetic Albino Rats

The plant Viscum album is used in folklore medicine to treat various diseases most especially diabetes mellitus. In this study, the antidiabetic potentials of the methanolic extract of Viscum album leave were evaluated using alloxan induced diabetes rats. Diabetes was induced using alloxan and 60mg/kg body weight. The diabetic rats were treated 1500 and 750 mg/kg body weight of viscum album leave extract and glinbenclamide was used as standard drug. During administration of extract, blood glucose level and body weight of the rat were being monitored at three days interval. There was a significant decrease in blood glucose level and body weight at three days interval. There was significant increases in (p&lt;0.05) in alloxan induced group after 21 days oral administration of the extract at 1500 and 750 mg/kg. Body weight shows significant reduction in total cholesterol, triglyceride, low lipid density, lipo protein when compared to diabetic control and high density lipo protein showed significant increase (&lt;p0.05) when compared to the diabetic control. Viscum album can be used in management of diabetes mellitus.

Cardio protective activity of Sargassum wightii on isoproterenol induced myocardial stress in rats

The aim of this investigation is to determine whether the methanolic extracts of Sargassum wightii can protect rats against isoproterenol-induced myocardial infarction. Four different groups of rats (6 rats in each group) were taken; where group 1 comprised of normal untreated rats, group 2 was injected with Isoproterenol (synthetic catecholamine), group 3 was considered as standard and hence, was injected with Isoproterenol + Simvastatin and group 4 was treated with Isoproterenol + Sargassum wightii’s extract. Cardioprotective effects of Sargassum wightii was observed via the changes in the lipid profile, cardio marker enzymes and through histopathological studies. Rats treated with the extract of S. wightii showed a significant reduction in total cholesterol, LDL-cholesterol, serum triglycerides and increase in HDL- cholesterol level indicating an undamaged myocardial membrane. Likewise, low enzyme activity in Sargassum wightii treated rats clearly indicated the cardioprotective effects of Sargassum wightii. Histopathological studies were also done to observe the changes on the rats at the tissue level and no pathological changes were observed in Sargassum wightii treated rats. Hence, methanolic extract of Sargassum wightii is evidenced to possess cardioprotective activity against myocardial infarction.

The effect of Brassica vegetables on blood glucose levels and lipid profiles in adults. A systematic review and meta-analysis.

Previous studies on the effect of Brassica vegetables on blood glucose and lipid profile have reported inconclusive findings. Due to the high prevalence of glucose and lipid metabolism disorders and their importance as predictors of chronic diseases, the present meta-analysis was performed to clarify the effect of Brassica vegetables on blood glucose and lipid profile. A systematic search of the databases of PubMed, Scopus, and Cochran Library was performed up to October 2020. All randomized controlled trials (RCTs) that examined the effect of Brassica vegetables on blood glucose and lipid profile were included in the study. The search results were limited to English-language publications. Finally, nine RCTs, including 548 participants, were selected for the present study. Pooled analysis indicated a significant reduction in total cholesterol (TC) (SMD=-0.28, 95%CI: 0.48 to 0.08; p= 0.005) following Brassica vegetables consumption. Overall, Brassica vegetables had no significant impact on serum levels of triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting blood sugar, and glycated hemoglobin. Consumption of Brassica vegetables had a statistically significant effect on TC concentration. However, further high-quality studies are needed to firmly establish the clinical efficacy of these plants.

EFFECTS OF OVER−DAY AND OVERNIGHT FASTING ON THE HEMATOLOGICAL, BIOCHEMICAL AND OXIDATIVE PROFILE OF HEALTHY DOGS

The influence of the circadian rhythm on canine laboratory parameters is yet to be elucidated. This study aimed to investigate possible fluctuations that occur on laboratory tests of healthy dogs following overnight and over−day fasting. For this purpose, 20 adult clinically healthy dogs were enrolled in the study. Venous blood samples were obtained 7:00 am (ONF, overnight fasting) and at 7:00 pm (ODF, over−day fasting) at the same day, following a 12−hour period of respectively overnight and over−day fasting for hematological, biochemical and oxidative stress assessment. The erythrogram showed significant reduction of red blood cells, hemoglobin, hematocrit and mean corpuscular volume (MCV) measured by the cell counter following ODF. The only change seen on the leukogram was a lower lymphocyte count following ODF. No significant changes were found on platelet count, although ODF was associated with decreased mean platelet volume (MPV) and total plasma protein (TPP). ODF caused a significant reduction of total cholesterol, ALP, phosphate and triglycerides. On oxidative stress parameters, ODF reduced total oxidant capacity (TOC) and increased lipid peroxidation. In conclusion, the time of fasting can partly influence hematological, biochemical and oxidative stress parameters in dogs significantly, which warrants standardization of fasting period prior to laboratory tests in dogs, especially during research.

The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials.

The effect of tamoxifen administration on serum lipids in females remains unclear. The studies which have explored this topic have produced conflicting results, probably due to discrepancies in the length of the intervention, differences in baseline variables or other factors. To answer this research question, we decided to conduct this systematic review and meta-analysis to assess the effects of tamoxifen on the lipid profile in women. A comprehensive search was conducted in Web of Science, Scopus, PubMed/Medline and Embase, from the inception of these databases up to June 2021. We used a random effects meta-analysis to generate the combined results. The overall findings were generated from 18 eligible trials. As compared to placebo, tamoxifen led to a notable reduction of the total cholesterol (TC) (WMD: -23.03mg/dL, 95% CI: -25.94 to -20.12, P˂0.001), and the low-density lipoprotein-cholesterol (LDL-C) (WMD: -18.68mg/dL, 95% CI: -24.31 to -13.04, P˂0.001). However, tamoxifen did not alter triglycerides (TG) concentrations (WMD: +1.06mg/dL, 95% CI: -11.08 to 13.20, P=0.864) significantly. A pronounced reduction of the high-density lipoprotein-cholesterol (HDLC) was noted in the RCTs with a duration of ≤52weeks (WMD: -2.06mg/dL) and when tamoxifen was administered in participants with a BMI ≥25kg/m2 (WMD: -1.42mg/dL). Notable reductions in TC (WMD: -23.57mg/dL) and LDL-C (WMD: -19.21mg/dL) was detected when the dose of tamoxifen was ≥20mg/day. Moreover, a significant reduction of TC (WMD: -20.23mg/dL) and LDL-C (WMD: -24.13mg/dL) was observed in the RCTs with a duration of ≤52weeks. Tamoxifen can alter the lipid profile in females, particularly by decreasing TC, LDL-C and HDLC. Tamoxifen can further reduce TC and LDL-C if the dose of administration is ≥20mg/day, the treatment duration is ≤52weeks and if it prescribed in subjects with dyslipidemia.

Effect of Plant-Derived n-3 Polyunsaturated Fatty Acids on Blood Lipids and Gut Microbiota: A Double-Blind Randomized Controlled Trial.

BackgroundSeveral cardioprotective mechanisms attributed to n-3 polyunsaturated fatty acids (PUFAs) have been widely documented. Significant interest has recently focused on the role of human gut microbiota in metabolic disorders. However, the role of plant-derived n-3 PUFAs on blood lipid profiles is controversial and the effect on gut microbiota is still unclear.ObjectivesWe aimed to perform a double-blind randomized controlled trial to test the effect of plant-derived n-3 PUFAs on the blood lipids and gut microbiota of patients with marginal hyperlipidemia.MethodsAccording to the inclusion and exclusion criteria, 75 participants with marginal hyperlipidemia were randomly assigned to the intervention group (supplied with n-3 PUFA-enriched plant oil) or control group (supplied with corn oil), respectively, for a 3-month treatment. Participants and assessors were blinded to the allocation. The primary outcomes of the trial were the changes in serum lipid levels. Secondary outcomes were changes in gut microbiota and metabolites. For the primary outcomes, we conducted both an intent-to-treat (ITT) analysis and a per protocol (PP) analysis. For the secondary outcomes, we only conducted the PP analysis among the participants who provided fecal sample.ResultsFifty-one participants completed the trial. Relative to the control group, the n-3 PUFA supplementation resulted in significant reduction in total cholesterol (TC) levels (−0.43 mmol/L, 95% CI−0.84 to−0.01 mmol/L, P < 0.05). The n-3 PUFA supplementation was also associated with significantly increased relative abundance of Bacteroidetes in phylum level (P < 0.01; false discovery rate (FDR) corrected p = 0.11), and decreased the ratio between Firmicutes and Bacteroidetes (P < 0.05; FDR corrected p = 0.16). At genus level, the intervention of plant derived n-3 PUFAs resulted in a significant decrease in relative abundance of Phascolarctobacterium (P < 0.01; FDR corrected p = 0.18) and Veillonella (P < 0.01; FDR corrected p = 0.18) after the intervention.ConclusionsOur results demonstrated that plant-derived n-3 PUFAs beneficially affected the serum levels of TC and decreased the ratio between Firmicutes and Bacteroidetes during the 12-week intervention period, which might confer advantageous consequences for lipid metabolism and intestinal health.

Effect of Treatment with Cleome Scaposa DC and Cleome Viscose L on Plasma Cholesterol and Atherogenic Index

This study aims to evaluate the effect of Cleome scaposa DC and Cleome viscose L on the lipid profile in Albino rabbits. The goal of the study was to discover newer ways to treat hyperlipidemia. Thirty albino rabbits were randomly divided into three groups (n = 10, per group). The daily oral dosing of ethanol extract of Cleome scaposa DC and ethanol extract of Cleome viscose L was administered respectively to groups1 and 2, while group 3 was considered the control group. Blood samples were taken at the end of the first, second, and fourth weeks. There was significant reduction in total cholesterol (F2, 4 = 10.85, P &lt; 0.05), triglyceride levels (F2, 4 = 1.686, P &lt; 0.05) and low-density lipoprotein (LDL) levels (F2, 4 = 1.97, P &lt; 0.045) in the treated groups of albino rabbits. A significant increase was seen in high-density lipoprotein (HDL) levels (F2, 4 = 29.095, P &lt; 0.05) in both groups treated. Cleome scaposa and Cleome viscose decreased total cholesterol. Both the herbs possess various constituents, which would be beneficial for treating different diseases. Studies regarding the phytochemistry of these herbs will be required before knowing the mechanism of action.

Effects of nut consumption on blood lipid profile: A meta-analysis of randomized controlled trials

Background & aimsSeveral randomized controlled trials (RCTs) have assessed the effects of nut consumption on blood lipid profile. The aim of this study was to conduct a meta-analysis to quantitatively estimate the effects of nut consumption on blood lipid profile. Methods and resultsThe PubMed, EMBASE, Cochrane Library, and Google Scholar databases were systematically searched to identify RCTs examining the effects of nut intake on blood total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs) from inception until March 2021. A random-effects model was used to pool standardized mean differences (SMDs) and 95% confidence intervals (CIs). Potential publication bias was assessed using Begg's test and Egger's test. Sensitivity analysis was performed to assess the impact of each individual study on the pooled results. The meta-analysis showed that nut consumption had no significant effect on the blood lipid profile. However, there was a significant reduction in TC (SMD: −2.89, 95% CI: −4.80, −0.98, I2 = 97.4) for pistachio consumption, and cashew consumption significantly increased HDL-C (SMD: 0.24, 95% CI: 0.04, 0.43, I2 = 0.0) compared with that in controls. There was no significant publication bias in the meta-analysis. The sensitivity analysis showed that removing one study at a time did not change the significance of the results. ConclusionThere was no overall effect of nut consumption on lipid profile, and the results may vary depending on nut type. We found that pistachio consumption may reduce TC levels, while cashew consumption increases HDL-C. Registry numberPROSPERO CRD42021249147.

The Effects of Capsinoids and Fermented Red Pepper Paste Supplementation on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

The present systematic review and meta-analysis were conducted in order to investigate the effects of capsinoids and fermented red pepper paste (FRPP) supplementation on lipid profile. Relevant studies were identified by searches of five databases from inception to November 2021 using relevant keywords. All clinical trials investigating the effect of capsinoids and FRPP on total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were included. Out of 1,203 citations, eight trials that enrolled 393 participants were included. Capsinoids and FRPP resulted in a significant reduction in TC (weighted mean differences [WMD], -9.92 mg/dL; 95% confidence interval [CI], -17.92 to -1.92; p = 0.015) but no significant changes in TG (WMD, -19.38 mg/dL; 95% CI, -39.94 to 1.18; p = 0.065), HDL-C (WMD, 0.83 mg/dL; 95% CI, -0.76 to 2.42; p = 0.305) and LDL-C (WMD, -0.59 mg/dL; 95% CI, -4.96 to 3.79; p = 0.793). Greater effects on TC were detected in trials performed on duration lasting less than twelve weeks, mean age of > 40, both sexes, and sample size of > 50. TG was reduced by using FRPP in studies conducted on mean age of > 40. HDL-C increased by using FRPP in studies conducted on duration of < 12 weeks, mean age of > 40, and sample size of ≤ 50. Overall, these data provided evidence that capsinoids and FRPP supplementation has beneficial effects on TC but not TG, HDL-C, and LDL-C.

Edible Green Solvent for Optimized Catechins Extraction from Green Tea Leaves: Anti-Hypercholesterolemia.

Catechin polyphenols are the major bioactive ingredients in green tea with various human health benefits. Extraction of catechins from green tea (GTE) leaves at optimized standard conditions is still a challenging approach. An optimized, rapid, and economic extraction method is industrially needed. We hypothesized that certain extraction techniques in the presence of natural polymers and antioxidants might improve GTE catechin extraction yield and its biological activity. The effect of microwave (30–60 seconds irradiation in a typical kitchen microwave) assisted extraction (MAE) and ultrasonic assisted extraction (UAE) techniques were evaluated separately and in combination. To study the effect of the extraction solvent, nine edible green solvent combinations were investigated namely water, ascorbic acid, chitosan/ascorbic acid, carboxymethylcellulose /ascorbic acid, methylcellulose /ascorbic acid, chitosan/methylcellulose/ascorbic acid, methylcellulose, chitosan/acetic acid, and ethanol. The amounts of extracted catechins from green tea leaves were quantified with HPLC-UV.Data showed that the use of MAE & UAE technique was the optimal in producing a higher extraction yield of catechins. Chitosan/ascorbic acid was the optimized solvent with high extraction efficiencies of catechins. Studies in high fat diet fed animals demonstrated significant reduction of total cholesterol and LDL-C by GTE after 3 weeks of oral daily administration. In conclusion, efficient extraction, and stabilization of catechins from green tea leaves demonstrated a significant lowering of high fat diet-mediated elevation in blood cholesterol and LDL-C levels.

Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund.

IntroductionHeterozygous familial hypercholesterolemia (FH) is characterized by an elevated plasma low-density lipoprotein cholesterol (LDL-C) concentration despite intensive statin and ezetimibe therapy, which significantly increases the cardiovascular risk.AimThe study evaluated the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, in reducing lipids in patients with FH.Material and methodsThis was a single-center analysis of 22 patients diagnosed with FH treated with the PCSK9 inhibitors under the drug program of the National Health Fund. The follow-up interviews and laboratory tests were performed at baseline (22 patients), 3 months (22 patients) and 15 months (9 patients) after the first dose of PCSK9 inhibitors.ResultsThe mean (SD) baseline level of the total LDL-C fraction was 4.7 ±1.6 mmol/l in the whole group of patients and was significantly reduced after 3 and 15 months of PCSK9 inhibitors therapy to 1.7 ±1.6 and 1.6 ±1.1 mmol/l, respectively. The average percentage of reduction in LDL-C level was 64.9 ±23.7% after 3 months and 66.9 ±18.4% after 15 months. In comparison with baseline, a significant reduction in total cholesterol was observed at both time points (p <0.0002). There were no adverse cardiovascular events or significant growth in the level of alanine transaminase, creatinine, and creatine kinase throughout the study.ConclusionsPatients with FH treated with PCSK9 inhibitors achieved a significant reduction of LDL-C and total cholesterol with the safety of this treatment in follow-up.

Effects of whole peanut within an energy-restricted diet on inflammatory and oxidative processes in obese women: a randomized controlled trial.

Peanut consumption has little effect on body weight, despite its high energy density and is associated with reduced cardiovascular disease risk. Based on previous research, we hypothesized that the consumption of whole peanut would be associated with greater improvements in body composition, lipid profile, and biomarkers of inflammation and oxidative stress. Twenty-four women with obesity [body mass index (BMI) > 30 kg m-2 ], 33.1 ± 8.7 years old, were assigned to three groups and consumed 56 g of whole peanut (WP), skinned peanut (SP), and no peanut (NP) and consumed energy-restricted diets (250 kcal d-1 less than their customary diet) for 8 weeks. WP group lost an average of 3.2kg, while SP group lost 2.6kg and the NP group 1.8kg. However, only the groups that consumed peanuts showed a significant reduction in BMI. WP group presented lower body weight, BMI, waist circumference, total lean mass, and total body fat than the SP group in the eighth week. There was a significant reduction in total cholesterol and low-density lipoprotein (LDL) after 4 weeks of intervention, which was maintained in week-8 for the WP and SP groups. In addition, there was an improvement in platelets and plasma homocysteine with WP group. Our results suggest that the regular intake of the whole peanut as part of an energy-restricted diet showed health benefits since it enhanced body weight loss, besides improving body composition and reducing cholesterol, platelets, and homocysteine concentrations. © 2021 Society of Chemical Industry.

170 Evaluation of endothelial function in dyslipidaemic patients treated with anti-PCSK9 monoclonal antibody

Abstract Aims According to new Guidelines, the use of an anti-PCSK9 monoclonal antibody in combination is recommended in secondary prevention in patients with very high risk who do not reach the target with the maximum tolerated dose of statin and ezetimibe, and in those patients with very high-risk familial hypercholesterolemia. The therapy is always combination, while the single treatment with anti-PCSK9 monoclonal antibody is indicated in patients with statin intolerance. The present study aims to determine the cardiovascular effects that are highlighted in the treatment of dyslipidaemia with the anti-PCSK9 monoclonal antibody, especially as regards the endothelial function (using the non-invasive methods of EndoPAT), the arterial stiffness (using the non-invasive methods of SphygmoCOR) and the effective improvement on the lipid profile (reduction total cholesterol, LDL and triglycerides). Methods The study is a single-centre prospective study enrolling 47 patients in primary and secondary prevention with non-target LDL cholesterol. Patients were evaluated and enrolled from April 2019 to June 2020 (recruitment period). The average follow-up was 12 weeks, from intaking one of anti-PCSK9, Alirocumab 75 or 150 mg and Evolocumab 140 mg. The scheduled evaluations of the enrolled population were before the beginning of the therapy and after a period of 12 weeks. Results After 12 weeks of treatment we demonstrated a statistically significant reduction in total cholesterol (P &amp;lt; 0.001) and LDL (P &amp;lt; 0.001). An important effect on the inflammatory profile was highlighted, resulting in a decrease in Hs-CRP at 12-weeks (P 0.057), associated with an improvement on endothelial function (P 0.003). Reduction of arterial stiffness was no significant (P 0.238). Conclusions Data confirm anti-PCSK9 monoclonal antibodies, associated with statins and/or ezetimibe to reach LDL target, improve significantly lipid profile and endothelial function. Furthermore anti-PCSK9 monoclonal antibodies are safe and practically free of side effects.

152 Effects of nutraceuticals on the control of the lipid-glycaemic structure and on endothelial protection, in patients with low cardiovascular risk profile

Abstract Aims Nutraceuticals are dietary supplements that contain a concentrated form of a presumed bioactive substance originally derived from a food. There is a relationship between the consumption of monacolin K from red yeast rice and maintenance of normal blood low density lipoprotein cholesterol (LDL-C) concentrations recognized by the European Agency on Food Safety. The present study evaluates the effects of a therapeutical association of nutraceuticals (a combination of containing fermented red rice, named Monacolin K and Coenzyme Q10) on lipo-glycaemic profile and on the vascular function evaluated as endothelial function and arterial stiffness (using the non-invasive methods of EndoPAT and SphygmoCOR). Methods The present is a single-centre prospective study enrolling 30 patients with low cardiovascular risk profile (SCORE risk, cardiovascular disease risk &amp;lt;10% at 10 years). Patients were consecutive enrolled from March 2019 to February 2020 (recruitment period). The average follow-up was 14 weeks, from intaking monacolin K 10 mg + Coenzyme Q10 10 mg. The scheduled evaluations of the enrolled population were: before the beginning of the therapy and after a period of 14 weeks. Results After 14 weeks of treatment we demonstrated a statistically significant reduction in total cholesterol (P 0.015) and LDL (P 0.003). An important effect on the inflammatory profile was highlighted, resulting in a decrease in Hs-CRP at 12-weeks (P 0.052), associated with a progressive reduction of arterial stiffness (P 0.063) and an improvement in endothelial function (P 0.048). Conclusions Data obtained suggest that formulations with natural nutraceuticals, especially fermented red rice, have a protective cardiovascular effect, not also through reduction of plasma lipids but in endothelial function and arterial stiffness improvement.

Вплив воглібозу на показники метаболічного контролю у хворих на цукровий діабет 1-го типу

Нові терапевтичні можливості контролю цукрового діабету (ЦД) виникли з відкриттям інгібіторів альфа-глюкозидази, які уповільнюють всмоктування вуглеводів у тонкому кишечнику. Мета дослідження — встановлення ефекту прийому воглібозу на параметри глікемічного контролю, ліпідного обміну і переносимості у хворих на цукровий діабет 1-го типу. Матеріали і методи. Критерії включення в дослідження: ЦД 1-го типу, вік від 26 до 48 років, рівень глікованого гемоглобіну (HbA1c) від 8 до 9 %. Під спостереженням перебувало 19 пацієнтів (7 чоловіків і 12 жінок, середній вік 37,2 ± 3,9 року, тривалість ЦД 8,5 ± 1,4 року. Результати. Протягом періоду спостереження (12 тижнів) рівень HbA1c вірогідно зменшився з 9,4 ± 0,6 % до 7,8 ± 0,4 % (р &lt; 0,05). На тлі додаткового прийому воглібозу спостерігалося вірогідне зниження рівня глюкози натще з 10,37 ± 0,36 ммоль/л до 7,39 ± 0,28 ммоль/л (р &lt; 0,01) і пост-прандіальної — з 12,29 ± 1,42 ммоль/л до 8,46 ± 0,64 ммоль/л (р &lt; 0,01). При цьому відзначалося вірогідне зниження вмісту загального холестерину (з 5,83 ± 0,11 ммоль/л до 5,38 ± 0,08 ммоль/л, p &lt; 0,05), тригліцеридів (з 1,82 ± 0,03 ммоль/л до 1,46 ± 0,03 ммоль/л, p &lt; 0,05) і холестерину ліпопротеїнів низької щільності (з 3,41 ± 0,05 ммоль/л до 3,37 ± 0,04 ммоль/л). Не спостерігалося вірогідних змін показників холестерину ліпопротеїнів високої щільності. У двох обстежених осіб відзначалися несприятливі явища (метеоризм), що не потребувало відміни препарату. Висновок. Додатковий прийом воглібозу в дозі 0,9 мг/добу на тлі інсулінотерапії сприяє поліпшенню глікемічного контролю і ліпідного метаболізму, зменшенню добової дози екзогенного інсуліну і частоти гіпоглікемічних реакцій у хворих на ЦД 1-го типу.